Tracking the real-world effects of Piqray in Korea
Part of Cancer, Skin clinical trials.
This study monitors how well and how safely Piqray works for people in Korea in routine care. You may be invited if your breast cancer matches specific genetic and receptor test results and you are starting Piqray for the first time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or spread breast cancer that is hormone-receptor positive, HER2-negative, and has a PIK3CA mutation
- You have already tried hormone-based (endocrine) treatment, and now you will start Piqray for the first time
- You are able and willing to sign written consent
- You do not have a medical allergy or other reason you cannot take Piqray under Korea’s approved instructions
- If you can become pregnant, you must not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at real-world safety data for patients in South Korea who are taking Capivasertib as prescribed by their doctor according to the approved label. It helps ensure the drug continues to be safe and effective for people who need it.
This study follows breast cancer patients who are scheduled to receive radiotherapy at a National Cancer Center in Korea. By collecting information during and after treatment, researchers hope to better understand how patients do over time.
This study tests whether a new type of PET/MRI scan can help doctors see how well breast cancer treatment is working. It is a platform study, meaning it can evaluate different treatments, but the focus is on using this advanced imaging to monitor response.
This trial tests a new combination of two drugs (JS105 plus dalpiciclib and fulvestrant) against a standard combination (dalpiciclib plus fulvestrant) for people whose breast cancer has a PIK3CA mutation. The goal is to see if adding JS105 helps control the cancer longer.
This trial tests a new drug, JYP0035, combined with fulvestrant for people with a specific type of advanced breast cancer that has a PIK3CA mutation. The goal is to see if this combination can help control the cancer better than standard treatments.
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.